The First Wearable Cancer Drug and the 2.25 Million Infusion Hours Nobody Has to Build

Thirteen minutes. That's how long Sarclisa Escena takes to deliver a cancer drug that used to require three hours in an infusion chair, an IV line, and a nurse standing by to manage reactions that hit one in four patients. The FDA approved it on July 9, making it the first cancer drug ever delivered by an on-body injector — a device roughly the size of a deck of cards that a patient sticks to their skin, presses a button, and walks away from. Days earlier, the agency cleared Keytruda QLEX for 38 tumor types. Administration time: one minute, down from thirty.

These are not incremental improvements. They are the two largest cancer drugs in the world quitting the infusion chair in the same week, and the math of what that frees has not been done.

So I did it.

The $46.7 Billion IV Exodus

Three cancer drug families now have subcutaneous alternatives that eliminate IV infusion entirely. Combined 2025 worldwide revenue: $46.7 billion.

Darzalex FASPRO launched in 2020 and has already converted most patients, freeing an estimated 4.8 million chair-hours annually. That transition proved the model works. But Keytruda and Sarclisa Escena are arriving into a healthcare system that has gotten measurably worse since Darzalex first moved to subcutaneous, and their combined capacity impact is significant enough to quantify.

The Infusion Crisis Nobody Can Staff Their Way Out Of

The United States has a deficit of 78,000 infusion-certified nurses, according to Mordor Intelligence's 2025 market analysis. Sixty-four percent of infusion centers report staffing shortages. More than half experience overbooking on a frequent or constant basis, per a Becker's Hospital Review / LeanTaaS survey. Median infusion nurse wages have climbed 12% year-over-year to $42 per hour, and turnover runs at 22%, adding $18,000-$24,000 in replacement costs per nurse.

Meanwhile, cancer diagnoses crossed two million per year for the first time in 2024. That's 5,365 new cases every day. Oncologist density is declining, from 15.9 to 14.9 per 100,000 adults 55+ over the past decade, and 68% of US counties face oncologist retirement risk within five years. Freestanding infusion centers are growing at a 12.54% compound annual rate because hospitals can't keep up, and they're projected to overtake hospital outpatient departments in capacity by 2029.

More patients. Fewer nurses. Fewer oncologists. More chairs needed, and nobody to sit behind them. Build your way out? A new ambulatory infusion center costs $5-15 million and takes 18-24 months. Capacity is needed now.

The Chair-Hour Liberation Math

I calculated the annual US infusion chair-hours eliminated by the two new IV-to-SC conversions, counting only the drug-specific infusion time removed from each visit, not the full chair booking, because most cancer patients receive combination regimens where other IV drugs still occupy the chair.

Sarclisa has one-quarter the patients of Keytruda but nearly double the chair-hours freed. Simple physics explains the gap: Sarclisa's IV infusion is six times longer. Each OBI visit reclaims almost three hours. Keytruda's IV infusion was only half an hour to begin with, a shorter bag but strapped to a vastly larger patient population.

What 2.25 Million Hours Buys

An average US infusion center chair generates roughly 2,600 productive hours per year (10 hours per day, 260 working days). Dividing 2.25 million freed hours by 2,600 yields 865 infusion chairs, the functional equivalent of approximately 43 new infusion centers at 20 chairs apiece. Construction cost of 43 centers at $5-15 million each: $215 million to $645 million. SC conversion delivers equivalent capacity for the cost of a reformulation and a new label.

Translated to labor: 2.25 million hours at the $42/hour median infusion nurse wage equals $94.5 million per year in freed nursing capacity, or 1,082 full-time nurse equivalents redirected from hanging bags to treating the next wave of patients. Against a national deficit of 78,000 infusion-certified nurses, that's 1.4% of the gap. Not transformative on its own, but it compounds.

Add Darzalex FASPRO's historical 4.8 million hours, and the three anti-CD38/checkpoint families alone have freed over 7 million chair-hours annually, the equivalent of 2,700 infusion chairs, or 135 centers that were never built and never needed to be.

The Device That Made Sarclisa Wearable

Keytruda QLEX uses Alteogen's berahyaluronidase technology, an enzyme that temporarily loosens the subcutaneous tissue to accept a large drug volume through a standard syringe. Darzalex FASPRO uses Halozyme's competing ENHANZE platform, the same hyaluronidase technology behind Rituxan HYCELA, Herceptin HYLECTA, and PHESGO. All of these are syringe-delivered, but Sarclisa Escena is different. It uses Enable Injections' CirCLIQ on-body injector, a wearable device from the enFuse platform: push a button, a hidden 30-gauge needle deploys automatically, the drug infuses hands-free over roughly 13 minutes, then the needle retracts and the device is discarded. No syringe. No vial. No healthcare professional required for the injection itself. In IRAKLIA, the Phase 3 trial that won FDA approval, infusion-related reactions dropped from 25% on IV to 1.5% on the OBI, and 74.5% of patients preferred the wearable over IV.

This matters because the OBI isn't just a different route of administration. It's a different care model. A syringe still implies a clinic visit, a nurse, a sharps container. An on-body injector implies a patient at home, watching television, while a cancer drug administers itself. What separates "subcutaneous" from "wearable" is the difference between a shorter hospital visit and no hospital visit at all.

The Pipeline Behind the Pipeline

Halozyme's ENHANZE platform now has partnerships with Roche, J&J, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, GSK, Takeda, and others, ten commercialized products across more than 100 global markets, with projected royalty revenue hitting $1 billion by 2027. In June 2026, GSK signed an ENHANZE license specifically for antibody-drug conjugates, a rapidly growing class of targeted cancer therapy that has never been delivered subcutaneously.

The fact that Merck chose Alteogen over Halozyme for the world's biggest cancer drug signals a real competition forming in the hyaluronidase space. And Enable Injections' OBI represents a third path entirely: not just making the syringe faster, but making the syringe disappear. This is no longer a one-company infrastructure play. It's a platform war over who owns the IV-to-SC conversion layer for the next decade of oncology.

Limitations

Patient counts are estimated from revenue divided by net-of-rebate pricing, not actual registry data. Real patient populations could be 15-20% higher or lower depending on payer mix and discount structures. Transition timing adds uncertainty: Darzalex FASPRO took approximately three years to reach majority conversion, and Keytruda QLEX won't be available until late September 2026; the 2.25 million hours are projected at full adoption, not day-one reality.

Critically, my calculation counts drug-specific infusion time only. Roughly 70-75% of Keytruda patients receive combination regimens with other IV drugs. For those patients, converting Keytruda to SC shortens the visit by 30 minutes but does not eliminate the chair. The full 786,500 hours of Keytruda IV time do disappear from the system, but they don't all translate into freed chairs, only into shorter appointments and potentially higher throughput. By contrast, 25-30% of Keytruda patients on monotherapy can leave the infusion center entirely.

Sarclisa patients are also on combination regimens (always with pomalidomide-dexamethasone or carfilzomib-dexamethasone), but these co-administered drugs are oral or short IV infusions. The three-hour Sarclisa IV was often the binding constraint on the visit, so eliminating it likely eliminates most of the chair-time.

The Strongest Case Against

The strongest counterargument: SC conversions don't fundamentally change the oncology capacity crisis; they just redistribute it. Freed chair-hours are immediately absorbed by the growing patient population (2M+ diagnoses per year, rising). The 78,000-nurse deficit isn't primarily an infusion-time problem; it's a training pipeline, burnout, and compensation problem that reformulating three drugs doesn't address. Converting IV to SC may even reduce infusion center revenue in a system where chair-hour billing ($364-$660/hour, per CancerNetwork data) subsidizes other services. Some centers could face financial stress, not relief.

This is a real concern. Historically, healthcare efficiency gains are a story of demand expanding to fill every unit of freed capacity. But there is a meaningful difference between "more capacity in a system that can staff it" and "more capacity in a system that cannot." When 64% of centers can't hire enough nurses and 51% are overbooked, freed capacity doesn't get absorbed by marginal new patients; it gets absorbed by the backlog of patients already waiting. That is an improvement in care quality, even if it doesn't look like slack on a spreadsheet.

The Bottom Line

Two cancer drugs left the IV bag in the same week. One shrunk a three-hour infusion to a wearable patch. Its companion reduced a thirty-minute drip to a sixty-second shot. Together, they free 2.25 million chair-hours per year, the capacity equivalent of 43 infusion centers that nobody funded, approved, or built.

What to watch: Keytruda QLEX launches commercially in late September 2026. Track its uptake curve against Darzalex FASPRO's precedent (three years to majority conversion). If adoption is faster, which the 38-indication breadth suggests it could be, the chair-hour math accelerates. For investors, Halozyme's ENHANZE platform is the toll road of the IV-to-SC conversion wave, and its GSK deal for antibody-drug conjugates signals the next frontier. For patients and caregivers navigating treatment options: ask your oncologist about subcutaneous alternatives. If you're being infused with Keytruda or Sarclisa, a version exists that could give you back three hours of your day, or let you spend treatment day at home.

The US infusion system has a 78,000-nurse deficit it cannot train its way out of and a 2-million-patient-per-year demand curve it cannot build its way under. Drug delivery — not hospital construction — might be the fastest path to closing the gap.